Pages

Monday, November 18, 2024

Fw: Ref.: (LML) Continuing Impacts of Training New Hansenologists in Brazil

 

 

Leprosy Mailing List –  November 18,  2024

 

Ref.:  (LML) Continuing Impacts of Training New Hansenologists in Brazil

From:  Claudio Salgado, Pará, Brazil


 

Dear Pieter,

Continuing with the impacts of the training course for new hansenologistas (18 in 2023, and more 19 at the end of November, 2024) in the state of Mato Grosso, Brazil, an event that had not occurred for over 40 years, last week we had two more important advances that I would like to share with colleagues.


The first was a technical note from the Regional Medical Council of the State of Mato Grosso, an agency with constitutional responsibilities for overseeing and regulating medical practice, drafted after a public hearing primarily addressing the lack of alternative medications to multidrug therapy. The public hearing, which included representatives from various institutions, from the Ministry of Health to social movements, was a success. The result was the formation of the first technical chamber on Hansen's Disease that we are aware of within a regional medical council, followed by the publication of the technical note, which I attach in Portuguese, and summarize the main points below.


The Technical Note from the Regional Medical Council of Mato Grosso (CRM-MT) on Hansen's Disease highlights several important advances in the treatment and management of the disease in the state. Here are the main points:


1. Adoption of Substitute Therapeutic Schemes: The technical note recommends the immediate availability of medications such as clarithromycin and levofloxacin for use in substitute therapeutic schemes, according to WHO and PCDT guidelines, to meet the growing demand in the state of Mato Grosso.


2. Review of the Brazil Clinical Protocol and Therapeutic Guidelines (PCDT): An urgent review of the Hansen's Disease PCDT was requested to allow flexibility in treatment duration and enable changes in the therapeutic scheme based on clinical decisions, potentially extending treatment beyond the conventional 12 months. Resistance to essential drugs, such as Rifampicin, was one of the central themes discussed. Bacterial resistance, exacerbated by treatment interruption, can result in a higher risk of complications and disease spread. The difficulty in measuring the percentage of bacterial resistance using molecular biology techniques, as defined in the PCDT, was highlighted, considering that there are molecular sensitive rifampicin strains that, however, show resistance in other experiments; the molecular mechanisms of bacterial resistance to clofazimine are unknown; and there are bacterial resistance sites to dapsone that are not examined by the technique currently provided by the Ministry of Health for PQT-U resistance assessment. Additionally, it was discussed that individual enzymatic-metabolic issues can lead to different responses to the standard therapeutic scheme, further complicating the use of just one therapeutic scheme, for the same duration, for all patients.


3. Monitoring and Control: Implementation of a robust system for monitoring prescriptions and treatment adherence, focusing on substitute medications and training of health professionals.


4. Training and Continuing Education: Regular training sessions for health professionals on managing Hansen's reactions and new therapeutic approaches, in addition to ensuring the integration of family health strategies by specialized doctors.


5. Social Support for Patients: Strengthening the support network for patients in collaboration with social movements, ensuring continuous access to treatment and necessary support.


6. Post-Treatment Semiannual Control: Implementation of simplified neurological and clinical evaluations every six months to monitor late complications of Hansen's Disease, such as neuritis and muscle atrophy.


These advances aim to improve the control and treatment of Hansen's Disease in Mato Grosso, addressing challenges such as drug resistance and the need for alternative therapeutic schemes.


Subsequently, we had a meeting coordinated by the Court of Auditors of the State of Mato Grosso, bringing together specialists and authorities from various fields to discuss the Hansen's Disease scenario in Mato Grosso, its impacts, barriers in combating the disease, and the necessary strategies to change the current panorama, seeking concrete solutions together and making firm commitments to transform the reality of Hansen's Disease in the state.


At the seminar "Building Actions for a Hansen's Disease-Free Mato Grosso," in addition to the SBH, the Mato Grosso School of Public Health, and the Health Secretary, representatives from various state public institutions, social movements, and representatives from over 100 municipalities in Mato Grosso were present. At the end of the event, 20 recommendations were issued for the municipalities, all aimed at better diagnosis, treatment, and follow-up of Hansen's Disease patients in the state, with the understanding that there is a significant expanding endemic that needs to be adequately controlled.


Finally, the book "Hansen's Disease in Brazil: Mato Grosso in Focus" was launched, which critically discusses the epidemiology of the endemic worldwide, in Brazil, and in Mato Grosso, the concept of "elimination" and its consequences for the planet, classification, new complementary exams, treatment, and patient follow-up. The book can be read here, in Portuguese: https://www.tce.mt.gov.br/uploads/flipbook/livro-hanseniase/index.html.


I believe these are important news items for the LML readers, considering the current situation of Hansen's Disease in the world.

 

Claudio Guedes Salgado, MD, PhD

 

Full Professor

Institute of Biological Sciences

Pará Federal University


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/8774b7f7-4664-49d0-be8f-4e666561da93n%40googlegroups.com.

Saturday, November 9, 2024

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. November 2024.

 

Leprosy Mailing List –  November 9,  2024

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy. November 2024.

From: Roos Geutjes and Upasana Regmi, Amsterdam, the Netherlands 




 


Dear colleagues, 

This month, we're excited to share that American Leprosy Missions has announced the start of a Phase 1b clinical trial for LepVax, the first vaccine developed specifically for leprosy. The goal of this trial is to demonstrate vaccine safety and immune response in healthy individuals in a leprosy-endemic area of Brazil. For more details on this milestone and other news, check the 'News and Events' section at the bottom of this overview.

In this issue, you'll find a wealth of valuable resources:

  • Research highlights: Discover studies addressing disability and quality of life among leprosy patients in India, Tanzania, and Guinea, as well as innovative drug delivery approaches and recent findings on biomarkers predicting leprosy reactions.
  • Global updates: This includes new WHO insights into progress on the 2030 elimination targets, paired with commentary from Dr. Paul Saunderson on tackling the challenges ahead.
  • Engaging articles: From community engagement techniques to social behavior change materials, there's plenty for field teams to explore and apply.
  • Unique case reports: Featuring rare clinical presentations and lessons learned.

As always, we encourage you to explore the latest research and resources on Infolep and InfoNTD to stay informed and engaged.




Warm regards,


Roos Geutjes and Upasana Regmi

www.infolep.org
info@infolep.org







Highlighted Publications



Impact of climate change on the rights of people affected by leprosy-related disability: a human rights approach 
Ahmed A. African Journal of Law, Ethics and Education. 2024. 


Global leprosy (Hansen disease) update, 2023: Elimination of leprosy disease is possible – Time to act! 
World Health Organization. 2024. 


Measuring the quality of life of people with severe leprosy and lymphatic filariasis disability in India using an informal, intervention-focused, contextual, and integrated tool for NTD disability 
Anand S, Kant Singh R, John A, et al. Leprosy Review. Lepra. 2024; 95 (3): 1-15. 


Burden of leprosy and associated risk factors for disabilities in Tanzania from 2017 to 2020 
Mrema G, Hussein A, Magoge W, et al. PLOS ONE. Public Library of Science (PLoS). 2024; 19 (10): 1-13. 


Frequency and Factors Associated with Disabilities among Leprosy Patients Admitted to the Kindia Disability Prevention and Physical Rehabilitation Centre (Pirp) in Guinea from 2017 to 2021 
Ibrahima Sory SS, Sidikiba S, Delphin K, et al. Tropical Medicine and Infectious Disease. MDPI AG. 2024; 9 (10): 1-9. 


Risk Factors for Psychological Impact and Stigma Among Leprosy Patients: A Systematic Review 
Rasyidi N, Yusuf A, Tristiana D. Indonesian Journal of Global Health Research. 2024. 


Ecuador Towards Zero Leprosy: A Twenty-Three-Year Retrospective Epidemiologic and Spatiotemporal Analysis of Leprosy in Ecuador 
Hernandez-Bojorge S, Gardellini T, Parikh J, et al. Tropical Medicine and Infectious Disease. MDPI AG. 2024; 9 (10): 1-18. 


Leprosy-related disability in children and adolescents under 15 years old in Brazil: evaluation of macro-regional disparities from 2001 to 2022 
Barbosa-Lima R, Vivian GF, Pinto MC, et al. Journal of Health &amp; Biological Sciences. Instituto para o Desenvolvimento da Educacao. 2024; 12 (1): 1-8. 


Knowledge, Attitudes, and Practices of Barangay Health Workers in Marawi City regarding Hansen's Disease. 
Pandapatan A, Dofitas B, Gervasio M, et al. Acta medica Philippina. 2024; 58 (17): 8-16. 






New publications

Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.



Communication Dynamics and Elite Perceptions: Assessing Government Policy Effectiveness in Sumberglagah Leprosy Village, Indonesia 
Hidayat E, Susilo D, Ansyah RHA, et al. Nyimak: Journal of Communication. 2024 


Clinically Suspicious Cases of Hansen's Disease at a Tertiary Care Hospital in South India: A Clinicopathological Study 
Shabnam A, Dennis Joseph L, Priyathersini N, et al. Cureus. Springer Science and Business Media LLC. 2024. 


Profile of Leprosy Patients at the Dermatology and Venereology Polyclinic of Dr. M. Djamil Padang Hospital in 2018-2021 
Habib El Binampiy Busnia , Gustia Rina , Deddy Herman. International Journal of Health and Medicine. Asosiasi Penelitian dan Pengajar Ilmu Hukum Indonesia. 2024; 1 (4): 120-133. 


Hubungan Dukungan Keluarga dengan Harga Diri Pada Pasien Kusta di Klinik Kulit dan Kelamin RSUD dr. Saiful Anwar Malang 
Suhermin Y. Jurnal Keperawatan Muhammadiyah. 2024. 


Cystic Subcutaneous Phaeohyphomycosis Caused by Cladophialophora Species in an Elderly Leprosy Patient 
Kumar PBP, Mala M, Jacob ES. Cureus. Springer Science and Business Media LLC. 2024. 


 IL-22 in Mycobacterium leprae-induced Nerve injury. 
Geng H, Bao F, Wang C, et al. The British journal of dermatology. 2024. 


Severity Classification of Electronic Health Records of Leprosy Patients Using Chicken Swarm Optimization-based LSTM Model 
Mehta J, Kumar A, Chakrabarti P. Library Progress International. 2024.


Th17 and T Regulatory Cytokines in Serum, Lesional Skin, and Stimulated Peripheral Blood Mononuclear Cell Culture Supernatants from Type 1 Leprosy Reaction Patients. 
Dabas S, Khurana A, Singh I, et al. The American journal of tropical medicine and hygiene. 2024. 


Análise dos casos de hanseníase no estado do Pará entre 2001 e 2020 
Alves Silva LE, Lima da Silva E, Borges da Silva DM, et al. Revista de Epidemiologia e Controle de Infecção. APESC - Associacao Pro-Ensino em Santa Cruz do Sul. 2024; 14 (2): 1-7. 


Aspectos diagnósticos e terapêuticos da hanseníase 
Felix gonçalves E, Bronzeado Cavalcanti Coutinho L, Clara Fernandes Diógenes A, et al. Imunologia e Doenças Infecciosas e Parasitárias - Edição I. Guilherme Barroso L. De Freitas. 2024. 


Hanseníase e avaliação neurológica simplificada: conhecimento de profissionais da atenção primária à saúde 
Freitas Maia AC, Tronconi IC, Sabeh ACB, et al. Revista Colombiana de Enfermería. Universidad el Bosque. 2024; 23 (1): 1-14. 


Impacto clínico das internações por sequelas de Hanseníase: uma análise epidemiológica abrangente 
Igarashi ÁT, Gonzaga PDV, Lana SC, et al. Brazilian Journal of Health Review. South Florida Publishing LLC. 2024; 7 (5): 1-10. 


Avaliação do grau de incapacidade neurofuncional dos pacientes com diagnóstico de Hanseníase 
Oliveira PDS, Silva AMFD, Neto LRDS, et al. Brazilian Journal of Health Review. South Florida Publishing LLC. 2021; 4 (4): 15870-15887. 


Fatores associados à percepção de estigma entre pacientes com hanseníase 
Guedes TRDMT. Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais. 2024. 


A assistência de enfermagem aos portadores de hanseníase assistidos pela atenção primária: revisão integrativa 
Oliveira DFD, Abreu JED, Oliveira GS, et al. Revista Ibero-Americana de Humanidades, Ciências e Educação. Revista Ibero-Americana de Humanidades, Ciencias e Educacao. 2024; 10 (6): 2024-2034. 


Perfil epidemiológico dos casos de hanseníase no município de tucuruí- pa entre 2018 e 2022 
Cruz DAV, Corrêa DCA, Pinheiro CJB, et al. Revista Contemporânea. South Florida Publishing LLC. 2024; 4 (10): 1-20. 


Sobreposição da hanseníase em redes de convívio domiciliar: gerações envolvidas, densidade de casos e perfis sociodemográfico e econômico em municípios do Norte e Nordeste do Brasil 
Boigny RN, Souza EAD, Reis ADSD, et al. Cadernos Saúde Coletiva. FapUNIFESP (SciELO). 2024; 32 (1): 1-15. 


Integração de ações de vigilância, prevenção e controle de doenças tropicais negligenciadas no SUS: perspectivas epidemiológicas e operacionais para Hanseníase e Doença de Chagas no sudoeste do estado da Bahia 
García GSM. Faculdade de Medicina, Universidade Federal do Ceará. 2024. 



Assessment of the Degree of Neurofunctional Disability in Leprosy Patients in a Municipality in Bahia, Brazil 
Costa HB, Braga IO, Silva VSD, et al. Medicina (Ribeirão Preto). Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais. 2024; 57 (1): 1-14. 


Unveiling inflammatory biomarkers in multibacillary leprosy: the role of lymphocyte-platelet ratio in predicting leprosy reactions 
Trindade LC, da Paz AR, da Silveira Mendes M, et al. Archives of Dermatological Research. Springer Science and Business Media LLC. 2024. 


Exploring the dynamics of leprosy transmission with treatment through a fractal–fractional differential model 
Kubra KT, Ali R, Ujala B, et al. Partial Differential Equations in Applied Mathematics. Elsevier BV. 2024. 


A Clinico‐Pathological Study and Bacteriological Study of Leprosy Cases in a Tertiary Care Hospital 
Sunitha A, Deshpande N, Ramya C, et al. Research Journal of Medical Sciences. 2024. 


Streptococcus dysgalactiae subsp.-equisimilis as an emerging secondary pathogen in leprosy foot ulcers 
Ebineshan K, Pallapati M, Srikantam A. Iranian Journal of Microbiology. 2024. 


One-Pot Synthesis and Characterization of Dapsone-Loaded Zeolitic Imidazolate Framework-8 
Diniz JMCT, Martins JC, de Melo Amaral IM, et al. Journal of Cluster Science. Springer Science and Business Media LLC. 2024.


Temporal trends and spatial analysis of leprosy surveillance indicators in the municipalities of the state of Mato Grosso, 2008-2022 
Freitas LRSD, Duarte EC. Revista da Sociedade Brasileira de Medicina Tropical. FapUNIFESP (SciELO). 2024. 


Comparison of the clinical manifestations and histopathological results in leprosy: A 5-year retrospective study in a tertiary hospital 
Sari ARP, Siswati AS, Ferronika P, et al. Leprosy Review. Lepra. 2024; 95 (4): 1-7. 


A Contemporary Cross-Sectional Study on Oral Manifestations of Leprosy 
Thangavel G, Sabarinathan S, Annamalai S, et al. Journal of Communicable Diseases. Advanced Research Publications. 2024; 56 (3): 1-4. 


Epidemiología y clínica de los pacientes con lepra en un centro de referencia de Paraguay 
Re Domínguez ML, Olmedo OMA. Revista del Nacional (Itauguá). Instituto de Investigaciones en Ciencias de la Salud. 2024; 16 (3): 1-13. 


Hanseníase: muito além da pele – o impacto sistêmico e psicológico no paciente com a doença 
Zanuto T, Amália Santos Schiochet Pontes , Evelyn Thamara de Almeida Fortunato , et al. Brazilian Journal of Implantology and Health Sciences. Brazilian Journal of Implantology and Health Sciences. 2024; 6 (10): 1092-1104. 


Análise epidemiológica da hanseníase na região sudeste do brasil 
Bahia VGL, Pereira AAF, Neto JFDO, et al. Brazilian Journal of Implantology and Health Sciences. Brazilian Journal of Implantology and Health Sciences. 2024; 6 (10): 2719-2731. 


Incapacidades na hanseníase: uma revisão da literatura 
Fadel SR, Marques BG, Cajado JB, et al. Open Science Research XVI. Editora Científica Digital. 2024. 


Hanseníase em indígenas do estado do Tocantins: perfil de casos e análise de tendência, 2001-2022 
Almeida MCC, Martins NP, Monteiro GG, et al. Revista Eletrônica Acervo Saúde. Revista Eletronica Acervo Saude. 2024; 24 (10): 1-10. 


O tempo de diagnóstico da hanseníase em correlação com o grau de incapacidade: uma coorte de 5 anos em Campos dos Goytacazes 
Camara Jacyntho S, Carvalho Ulrick Dib J, Pellegrini Nahn Junior E. Anais da Semana Científica da Faculdade de Medicina de Campos. Faculdade de Medicina de Campos. 2024. 


Perfil epidemiológico da hanseníase em crianças e adolescentes menores de quinze anos no estado de sergipe: análise de dados entre 2012 e 2022 
Guimarães CV. Revista Contemporânea. South Florida Publishing LLC. 2024; 4 (10): 1-16. 


Clusters de alto risco dos casos por Hanseníase na região Nordeste do Brasil: Modelagem espaço-temporal retrospectiva e prospectiva 
Clemente GS, Almeida DHD. Research, Society and Development. Research, Society and Development. 2024; 13 (10): 1-14. 


Leprosy/Hanseníase: An Interdisciplinary and Epidemiological Analysis Amazônia Paraense -Vila Santo Antônio do Prata-PA. 
de Alcantara MDLB, Corbett CE, Brasil M. International Journal of Research and Scientific Innovation. RSIS International. 2024; XI (XV) : 334-355.






Case Reports

Unveiling the clinico-dermoscopic and histopathological correlation of histoid leprosy: A case series 
Meda S, Bonthu I, Seeram R, et al. Leprosy Review. Lepra. 2024; 95 (3): 1-12. 


Lepra: enfermedad reemergente 
Hincapie DAF, Rozo EFM, Agudelo LG, et al. Dermatology Mexican Megazine. 2024 


Ulcerative type 1 lepra reaction in borderline-tuberculoid leprosy 
Mushtaq S. Hansenologia Internationalis: hanseníase e outras doenças infecciosas. Instituto Lauro de Souza Lima. 2024. 


Diagnostic Enigma in a rare Case of Primary Neuritic Leprosy 
Ahmed S, Rahman A, Ahmed T, et al. Bangladesh Journal of Medicine. Bangladesh Academy of Sciences. 2024; 35 (3) : 214-217. 


Immune-Mediated Glomerulonephritis as Type 2 Lepra Reaction Posttreatment of Lepromatous Leprosy: A Case Report. 
Kantak D, Dsouza M. Indian journal of nephrology. 2024; 34 (5): 520-521. 


The First Case Report of Pulmonary Hypertension in Leprosy 
Siregar M, Wahidji V. Iranian Heart Journal. 2024. 


Erythema nodosum leprosum: condition developed by non-adherence 
Gladwin E, Patel M, Mistry M. International Journal of Pharmacy and Pharmaceutical Sciences. Innovare Academic Sciences Pvt Ltd. 2024. 


Erythematous lesions with Woronoff's ring like perilesional hypopigmented halo in a case of leprosy 
Mushtaq S. Hansenologia Internationalis: hanseníase e outras doenças infecciosas. Instituto Lauro de Souza Lima. 2024. 


Diffuse Lepromatous Leprosy with Lucio PhenomenonCaused by Mycobacterium leprae 
Kumalasari DN, Hendaria MP, Dewi AWK, et al. Journal of Mycology and Infection. Korean Society for Medical Mycology. 2024. 


Clinico-histological correlation of Hansen's disease at tertiary care centre 
Rishi P, Patel A, Shrivastava P, et al. Journal of Cardiovascular Disease Research. 2024. 


A Case of Anatopic Phenomenon in Dapsone Hypersensitivity Syndrome 
Devi S. K, Raviprakash D, Priyadarshini A, et al. Cureus. Springer Science and Business Media LLC. 2024. 


Analyzing the Vulnerability of Children of Recovered Leprosy Patients: A Case Study of a Leprosy Village in Vietnam 
Watanabe H, Vu Tuan Anh, Huynh Cong Ai, et al. JAPANESE JOURNAL OF LEPROSY. Japanese Leprosy Association. 2024; 93 (2): 39-47. 


Robust contact tracing and screening needed for leprosy control and protection of vulnerable children 
Pilaka K, Pallapati M, Jaladi Z, et al. The Iranian Journal of Microbiology. 2024. 


Cystic Subcutaneous Phaeohyphomycosis Caused by Cladophialophora Species in an Elderly Leprosy Patient 
Kumar PBP, Mala M, Jacob E. Cureus. 2024 


Lepromatous leprosy with respiratory failure in the City of Buenos Aires. 
Villa R. Medicina. 2024; 84 (5): 1042-1043. 


Erythema nodosum leprosum as the initial presentation of lepromatous leprosy. 
Hingtgen G, Mojica R, Beatty N, et al. JAAD case reports. 2024. 


Eritema nodoso centrofacial com apresentação semelhante a furúnculo em paciente de município da pré-amazônia maranhense 
Cruz DDSD, Barroso PMA, Silva TM, et al. Brazilian Journal of Health Review. South Florida Publishing LLC. 2024; 7 (5): 1-7. 


Análise integrada da hanseníase em um município hiperendêmico do Brasil 
Moreno FC, Medrado JJDS, Oliveira KAD, et al. CONTRIBUCIONES A LAS CIENCIAS SOCIALES. South Florida Publishing LLC. 2024; 17 (10): 1-20. 


Os desafios e dificuldades enfrentadas por portadores de hanseníase durante a pandemia da COVID-19 
Matos MOP, Anjos AAD, Macedo CG, et al. Revista Eletrônica Acervo Saúde. Revista Eletronica Acervo Saude. 2024; 24 (10): 1-13. 


Reação adversa grave à dapsona no tratamento da hanseníase 
Rodrigues MEG, Costa JEFD, Palitot EB. Hansenologia Internationalis: hanseníase e outras doenças infecciosas. Instituto Lauro de Souza Lima. 2024 


 







News & Events



Anvisa authorizes testing of the first vaccine against leprosy in Brazil (The Impartial) 


Indonesia launches final push to eliminate lymphatic filariasis, leprosy and yaws (World Health Organization) 


Global leprosy (Hansen disease) update 2023: Elimination of leprosy disease is possible – Time to act! Commentary: Dr Paul Saunderson (International Federation of Anti-Leprosy Associations) 


Stigma and mental wellbeing in relation to skin NTDs 
November 14, 2024, 13:00 CET  
This WHO Skin-NTDs  webinar will focus on stigma and mental wellbeing in relation to skin NTDs. 


Lepra launches its ambitious new 2024 - 2030 Global Strategy 
November 20, 2024, 19:00 GMT 
Join Lepra's special online premiere event to learn more about their new global strategy focused on "Health, Inclusion, and Innovation." This event will provide an in-depth look at how Lepra's innovative and inclusive approach empowers communities, builds resilience, and ensures sustainable care for those affected by leprosy and lymphatic filariasis. 


Second global meeting on skin-related neglected tropical diseases (skin NTDs) 
Save the date! March 24-26, 2025 
The World Health Organization (WHO) held its first global meeting on skin-related neglected tropical diseases (skin NTDs) on 27–31 March 2023 in Geneva, Switzerland. This meeting has built the foundation and momentum for the second global meeting to be held on 24–26 March 2025. The event demonstrates the collective commitment of the global skin-NTD community to achieving a key objective of the NTD road map: integration. 


Conference on Neglected Tropical Diseases 2024
May 2025; Nairobi, Kenya.
The 1st edition of the Conference on Neglected Tropical Diseases, organized by AME is tentatively scheduled in May 2025 in Nairobi, Kenya, as a hybrid meeting. The abstract-driven conference proposes a platform to disseminate new advancements, real-world data, implementation challenges, and novel governing models to discuss and generate solutions for cross-cutting topics and ultimately reduce the disease burden and societal impact of NTDs. This proposal supports the progress in foundational pillars of the WHO Roadmap by facilitating evidence-based program implementation, leveraging the cross-cutting approach, and providing a forum to discuss a paradigm shift toward country ownership of elimination programs.



Call for Proposals: RFA: Reaching the last mile: Addressing barriers to the implementation of the NTD interventions among Mobile and Migrant Populations (MMP) Coalition for Operational Research Neglected Tropical Diseases) 


Ivory Coast: Progress in a collective commitment towards "Zero Leprosy" by 2030 (Raoul Follereau) 


How do we shift the dial on some of leprosy's biggest and most stubborn problems? (The Leprosy Mission) 


Addressing Social Determinants of Health to Accelerate Disease Elimination 
November 14, 2024, 9:30-11:15 EST 
This webinar will explore tools and approaches to incorporate social determinants into programmatic actions to address health equity and increase effectiveness of activities, drawing from regional experiences and innovative frameworks. 


Call for Proposals: Mental Health Award - Accelerating scalable digital mental health interventions 
This call will fund research to evaluate and further develop scalable digital interventions to advance early intervention in depression, anxiety and psychosis. Funding amount: £3 to 7 million per project. The application must be submitted by 17:00 GMT on the 5th of December 2024.


Tropical Infectious Diseases Gordon Research Conference
February 2-7, 2024; Renaissance Tuscany Il Ciocco, Lucca, Italy
The theme of the conference is "Basic and Clinical Research Strategies for Tackling Tropical Infectious Diseases in a Globalized World". Registration is open and deadline is January 5, 2025.


Global Disability Summit 2025 
April 2-4, 2025; Berlin, Germany. 
The Global Disability Summit aims to galvanize global efforts to realize disability inclusion around the world. It is a mechanism bringing together a wide variety of high-level stakeholders, engaging and discussing the progress in disability inclusion: governments, multilateral agencies, the private sector, academia and civil society organizations, organizations of persons with disabilities, and foundations. 


22nd International Leprosy Congress (ILC) 
July 5-9, 2025; Bali Nusa Dua Convention Centra (BNDCC), Bali, Indonesia 
This year the 22nd International Leprosy Congress (ILC) will be held in Bali, Indonesia! The congress uphold the theme: "Towards a World with Zero Leprosy". The theme aims to enhance the evidence into the clinical care in leprosy early diagnosis and therapeutics in the global era and prepare to face the new perspective of dermatology practice. Abstract submission and early bird registration is open until November 30th.






Links



Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease
 


ALLF - Official website of the Association des Léprologues de Langue Française
 


LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 


InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)


ILEP newsletter archive


GPZL newsletter subscription


WHO Goodwill Ambassador's Leprosy Bulletin


Leprosy Review


Leprosy Review Repository (1928-2001)


Fontilles Revista de Leprología


Indian Journal of Leprosy


Hansenologia Internationalis


HARP - database of Hansen's Disease Antimicrobial Resistance Profiles




GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our
privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can
update your preferences or unsubscribe from this list at any time.






Copyright © 2024 Infolep, All rights reserved.
You are receiving this mail because you opted in at our website.

Our mailing address is:

Infolep

Wibautstraat 137-k

Amsterdam, 1097 DN

Netherlands


Add us to your address book



Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/5ef749dc-5aa5-4c7d-9cb1-cd043e6e89bcn%40googlegroups.com.